The document entitled, “Guidance for Industry, Institutional Review Boards,
Clinical Investigators, and Food and Drug Administration: Guidance on Informed
Consent for In Vitro Diagnostic Device Studies using Leftover Human Specimens
that are not Individually Identifiable,” describes the limited circumstances in which FDA
intends to exercise enforcement discretion regarding requirements for informed
consent.
